(0.09%) 5 136.25 points
(0.05%) 38 460 points
(0.17%) 17 876 points
(-0.25%) $83.64
(1.72%) $1.956
(0.34%) $2 355.10
(0.54%) $27.69
(1.66%) $937.45
(-0.15%) $0.933
(-0.35%) $10.99
(-0.29%) $0.798
(1.20%) $92.98
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.48%
@ $234.68
发出时间: 26 Apr 2024 @ 23:42
回报率: -0.35%
上一信号: Apr 26 - 03:08
上一信号:
回报率: -0.60 %
Live Chart Being Loaded With Signals
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally...
Stats | |
---|---|
今日成交量 | 369 691 |
平均成交量 | 470 161 |
市值 | 11.00B |
EPS | $0 ( 2024-02-21 ) |
下一个收益日期 | ( $5.63 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.80 |
ATR14 | $3.04 (1.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-23 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-04-24 | Rothblatt Martine A | Sell | 3 600 | Stock Options |
2024-04-24 | Rothblatt Martine A | Buy | 3 600 | Common Stock |
2024-04-24 | Rothblatt Martine A | Sell | 36 | Common Stock |
2024-04-24 | Rothblatt Martine A | Sell | 145 | Common Stock |
INSIDER POWER |
---|
-42.40 |
Last 100 transactions |
Buy: 76 860 | Sell: 189 720 |
音量 相关性
United Therapeutics Corp 相关性 - 货币/商品
United Therapeutics Corp 财务报表
Annual | 2023 |
营收: | $2.33B |
毛利润: | $2.07B (88.94 %) |
EPS: | $21.04 |
FY | 2023 |
营收: | $2.33B |
毛利润: | $2.07B (88.94 %) |
EPS: | $21.04 |
FY | 2022 |
营收: | $1.94B |
毛利润: | $1.79B (92.42 %) |
EPS: | $15.98 |
FY | 2021 |
营收: | $1.69B |
毛利润: | $1.56B (92.73 %) |
EPS: | $10.60 |
Financial Reports:
No articles found.
United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。